Review
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Methodol. Sep 26, 2014; 4(3): 144-150
Published online Sep 26, 2014. doi: 10.5662/wjm.v4.i3.144
Closer look at white-coat hypertension
Nurver Turfaner Sipahioglu, Fikret Sipahioglu
Nurver Turfaner Sipahioglu, Fikret Sipahioglu, Department of Family Medicine, Cerrahpasa Medical Faculty, Istanbul University, 34303 Istanbul, Turkey
Author contributions: Sipahioglu NT contributed to deciding the subject, writing the manuscript and revising the paper; Sipahioglu F contributed to language editing, finding references, polishing the format.
Correspondence to: Nurver Turfaner Sipahioglu, MD, PhD, Associate Professor, Department of Family Medicine, Cerrahpasa Medical Faculty, Istanbul University, Kaptanı Derya İbrahim Paşa Sokak, 34303 Istanbul, Turkey. nurverdi@gmail.com
Telephone: +90-532-4961773 Fax: +90-212-4143251
Received: November 27, 2013
Revised: July 23, 2014
Accepted: July 27, 2014
Published online: September 26, 2014
Processing time: 325 Days and 22.5 Hours
Abstract

This review aims to clarify novel concepts regarding the clinical and laboratory aspects of white-coat hypertension (WCHT). Recent studies on the clinical and biological implications of WCHT were compared with existing knowledge. Studies were included if the WCHT patients were defined according to the 2013 European Society of Hypertension guidelines, i.e., an office blood pressure (BP) of ≥ 140/90 mmHg, a home BP of ≤ 135/85 mmHg, and a mean 24-h ambulatory BP of ≤ 130/80 mmHg. WCHT studies published since 2000 were selected, although a few studies performed before 2000 were used for comparative purposes. True WCHT was defined as normal ABPM and home BP readings, and partial WCHT was defined as an abnormality in one of these two readings. The reported prevalence of WCHT was 15%-45%. The incidence of WCHT tended to be higher in females and in non-smokers. Compared with normotensive (NT) patients, WCHT was associated with a higher left ventricular mass index, higher lipid levels, impaired fasting glucose, and decreased arterial compliance. The circadian rhythm in WCHT patients was more variable than in NT patient’s, with a higher pulse pressure and non-dipping characteristics. Compared with sustained hypertension patients, WCHT patients have a better 10-year prognosis; compared with NT patients, WCHT patients have a similar stroke risk, but receive more frequent drug treatment. There are conflicting results regarding WCHT and markers of endothelial damage, oxidative stress and inflammation, and the data imply that WCHT patients may have a worse prognosis. Nitric oxide levels are lower, and oxidative stress parameters are higher in WCHT patients than in NT patients, whereas the antioxidant capacity is lower in WCHT patients than in NT patients. Clinicians should be aware of the risk factors associated with WCHT and patients should be closely monitored especially to identify target organ damage and metabolic syndrome.

Keywords: White-coat hypertension; Ambulatory blood pressure; Target organ damage; Glucose dysregulation

Core tip: There is contradictory information regarding the clinical presentations and prognosis of white-coat hypertension (WCHT). This review aims to summarize recent research and compare it to existing knowledge about WCHT. Published studies on the prevalence of WCHT, the associated target organ damage and cardiovascular markers, and WCHT patient prognosis were reviewed. WCHT may be a marker of future obesity and metabolic syndrome, is related to glucose dysregulation and left ventricular hypertrophy and may progress to sustained hypertension. Clinicians should be aware of the risk factors associated with WCHT, and patients should be closely monitored, especially to identify target organ damage and metabolic syndrome.